TLDR Secukinumab can cause hair loss, which may improve after stopping the medication.
Secukinumab, an IL-17A-targeting biological agent used for treating spondyloarthritis, can cause alopecia areata (AA) as a rare adverse effect. This case report details a 46-year-old female with SpA who developed an ophiasis pattern of AA while on secukinumab, with hair regrowth observed after discontinuing the medication. The report discusses the patient's clinical course, potential pathophysiological mechanisms, and reviews similar cases in the literature, emphasizing the need for awareness and management of secukinumab-induced AA and further research into tailored treatments.
37 citations,
December 2021 in “Cells” Alopecia areata severity and treatment response are linked to specific cytokine levels.
20 citations,
March 2019 in “Case Reports in Dermatology” IL-17 inhibitors for psoriasis may cause unexpected hair loss.
28 citations,
March 2018 in “Archives of Dermatological Research” [object Object]
1 citations,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
37 citations,
December 2021 in “Cells” Alopecia areata severity and treatment response are linked to specific cytokine levels.
1 citations,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
[object Object] 
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
